Clearside Overview Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®). Clearside’s SCS injection platform, utilizing the Company’s proprietary SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector and strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. Clearside’s first product, XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, is commercially available in the U.S. Quarterly Summary Show all Latest Quarterly Results Clearside Biomedical Announces Second Quarter 2022 Financial Results and Provides Corporate Update Clearside Biomedical Q2 2022 Financial Results and Corporate Update Call View All News Releases Aug 9 2022 Clearside Biomedical Announces Second Quarter 2022 Financial Results and Provides Corporate Update Aug 8 2022 Clearside Biomedical Enters into Non-Dilutive Financing Agreement with HealthCare Royalty Partners for up to $65 Million Aug 3 2022 Clearside Biomedical to Participate in Three Upcoming Investor Conferences in August 2022 View All Events H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference Aug 17, 2022 at 11:00 AM EDT View All Stock Quote Change Volume 52 Week High 52 Week Low Aug 14, 2022 5:02 AM EDT Data Provided by Refinitiv. Minimum 15 minutes delayed.